175 related articles for article (PubMed ID: 35349638)
41. Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma.
Martin-Broto J; Olarte-García A; Fernandéz-Rodríguez R; Ferreira MR; Carrasco-García I; Galvez-Montosa F; Rincon-Perez I; Peinado-Serrano J; Azinovic I; Guzman-Gomez L; Salgado L; Sevillano A; Ortega J; Alvarez C; Gutierrez A; Moura DS; Hindi N
Ther Adv Med Oncol; 2024; 16():17588359231225044. PubMed ID: 38288156
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Hassan R; Thomas A; Nemunaitis JJ; Patel MR; Bennouna J; Chen FL; Delord JP; Dowlati A; Kochuparambil ST; Taylor MH; Powderly JD; Vaishampayan UN; Verschraegen C; Grote HJ; von Heydebreck A; Chin K; Gulley JL
JAMA Oncol; 2019 Mar; 5(3):351-357. PubMed ID: 30605211
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
Grosso F; Jones RL; Demetri GD; Judson IR; Blay JY; Le Cesne A; Sanfilippo R; Casieri P; Collini P; Dileo P; Spreafico C; Stacchiotti S; Tamborini E; Tercero JC; Jimeno J; D'Incalci M; Gronchi A; Fletcher JA; Pilotti S; Casali PG
Lancet Oncol; 2007 Jul; 8(7):595-602. PubMed ID: 17586092
[TBL] [Abstract][Full Text] [Related]
44. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.
Sanfilippo R; Grosso F; Jones RL; Banerjee S; Pilotti S; D'Incalci M; Dei Tos AP; Raspagliesi F; Judson I; Casali PG
Gynecol Oncol; 2011 Dec; 123(3):553-6. PubMed ID: 21917307
[TBL] [Abstract][Full Text] [Related]
45. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
Barlesi F; Vansteenkiste J; Spigel D; Ishii H; Garassino M; de Marinis F; Özgüroğlu M; Szczesna A; Polychronis A; Uslu R; Krzakowski M; Lee JS; Calabrò L; Arén Frontera O; Ellers-Lenz B; Bajars M; Ruisi M; Park K
Lancet Oncol; 2018 Nov; 19(11):1468-1479. PubMed ID: 30262187
[TBL] [Abstract][Full Text] [Related]
46. Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.
Tewari D; Saffari B; Cowan C; Wallick AC; Koontz MZ; Monk BJ
Gynecol Oncol; 2006 Sep; 102(3):421-4. PubMed ID: 16797679
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study.
Kobayashi H; Iwata S; Wakamatsu T; Hayakawa K; Yonemoto T; Wasa J; Oka H; Ueda T; Tanaka S
Cancer; 2020 Mar; 126(6):1253-1263. PubMed ID: 31825533
[TBL] [Abstract][Full Text] [Related]
48. Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin.
Tavella K; Villanucci A; Vannini L; Lavacchi D; Montelatici S; Amunni G; Mazzei T
Anticancer Drugs; 2017 Apr; 28(4):465-468. PubMed ID: 28181940
[TBL] [Abstract][Full Text] [Related]
49. Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.
Dickson MA; Mahoney MR; Tap WD; D'Angelo SP; Keohan ML; Van Tine BA; Agulnik M; Horvath LE; Nair JS; Schwartz GK
Ann Oncol; 2016 Oct; 27(10):1855-60. PubMed ID: 27502708
[TBL] [Abstract][Full Text] [Related]
50. Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib.
Lee DW; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH; Kim TY; Han SW; Oh DY; Im SA; Kim TY; Lee Y; Kim H; Lee KH
Clin Cancer Res; 2021 Feb; 27(3):713-718. PubMed ID: 33139266
[TBL] [Abstract][Full Text] [Related]
51. Prolonged disease stability with trabectedin in two monorenal patients with retroperitoneal sarcoma.
Bruder F; Massa D; Barca M; Contu V; Airoldi M; Crova A
Tumori; 2014; 100(3):e63-6. PubMed ID: 25076252
[TBL] [Abstract][Full Text] [Related]
52. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial.
Sanfilippo R; Hindi N; Cruz Jurado J; Blay JY; Lopez-Pousa A; Italiano A; Alvarez R; Gutierrez A; Rincón-Perez I; Sangalli C; Pérez Aguiar JL; Romero J; Morosi C; Sunyach MP; Fabbroni C; Romagosa C; Ranchere-Vince D; Dei Tos AP; Casali PG; Martin-Broto J; Gronchi A
JAMA Oncol; 2023 May; 9(5):656-663. PubMed ID: 36995731
[TBL] [Abstract][Full Text] [Related]
53. Real-World Experience of Efficacy and Safety of Trabectedin in Patients with Soft Tissue Sarcoma: A Bicentric Retrospective Analysis.
Chaigneau L; Jary M; Nerich V; Hervieu A; Aubry S; Charon Barra C; Meynard G; Neumann F; Kalbacher E; Isambert N
Oncology; 2022; 100(12):633-644. PubMed ID: 36283345
[TBL] [Abstract][Full Text] [Related]
54. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Monk BJ; Colombo N; Oza AM; Fujiwara K; Birrer MJ; Randall L; Poddubskaya EV; Scambia G; Shparyk YV; Lim MC; Bhoola SM; Sohn J; Yonemori K; Stewart RA; Zhang X; Perkins Smith J; Linn C; Ledermann JA
Lancet Oncol; 2021 Sep; 22(9):1275-1289. PubMed ID: 34363762
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.
Rajan A; Heery CR; Thomas A; Mammen AL; Perry S; O'Sullivan Coyne G; Guha U; Berman A; Szabo E; Madan RA; Ballester LY; Pittaluga S; Donahue RN; Tsai YT; Lepone LM; Chin K; Ginty F; Sood A; Hewitt SM; Schlom J; Hassan R; Gulley JL
J Immunother Cancer; 2019 Oct; 7(1):269. PubMed ID: 31639039
[TBL] [Abstract][Full Text] [Related]
56. Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry.
Vincenzi B; Napolitano A; Comandone A; Sanfilippo R; Celant S; Olimpieri PP; Di Segni S; Russo P; Casali PG
Int J Cancer; 2023 Feb; 152(4):761-768. PubMed ID: 36196483
[TBL] [Abstract][Full Text] [Related]
57. Trabectedin in advanced soft tissue sarcoma: case series.
Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
[TBL] [Abstract][Full Text] [Related]
58. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer.
Solomon B; Callejo A; Bar J; Berchem G; Bazhenova L; Saintigny P; Wunder F; Raynaud J; Girard N; Lee JJ; Sulaiman R; Prouse B; Bresson C; Ventura H; Magidi S; Rubin E; Young B; Onn A; Leyland-Jones B; Schilsky RL; Lazar V; Felip E; Kurzrock R
Cancer Med; 2022 Jul; 11(14):2790-2800. PubMed ID: 35307972
[TBL] [Abstract][Full Text] [Related]
59. Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial.
Park K; Özgüroğlu M; Vansteenkiste J; Spigel D; Yang JCH; Ishii H; Garassino M; de Marinis F; Szczesna A; Polychronis A; Uslu R; Krzakowski M; Lee JS; Calabrò L; Arén Frontera O; Xiong H; Bajars M; Ruisi M; Barlesi F
J Thorac Oncol; 2021 Aug; 16(8):1369-1378. PubMed ID: 33845211
[TBL] [Abstract][Full Text] [Related]
60. Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials.
Chan DL; Rodriguez-Freixinos V; Doherty M; Wasson K; Iscoe N; Raskin W; Hallet J; Myrehaug S; Law C; Thawer A; Nguyen K; Singh S
Eur J Cancer; 2022 Jul; 169():74-81. PubMed ID: 35504244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
